V

Velocity Clinical Research | Valparaiso, IN

Research site

(Unclaimed)

Location

55 University Drive Suite 106, Valparaiso, Indiana, United States of America

Site insights

Top conditions

Top treatments

RGT001-075

Bupropion Hydrochloride

Naltrexone Hydrochloride

Parent organization

This site is a part of Velocity Clinical Research

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

3 of 5 total trials

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults

The main objective of Part A of this trial is to evaluate the safety and reactogenicity of mRNA-1189 in 18- to 30-year-old healthy adults, the main o...

Active, not recruiting

Epstein-Barr Virus Infection

Biological: mRNA-1189

Biological: Placebo

Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE) (INFORMUS)

A randomized, double-blinded, placebo controlled study intended to capture cardiovascular outcomes during real-world use of naltrexone/bupropion (NB).

Enrolling

Obesity

Drug: Placebo

Drug: Naltrexone-Bupropion (NB) Combination

Study of Once-Daily Oral RGT001-075 Compared With Placebo in Adults With Obesity or Are Overweight With Weight-Related Health Conditions (COMO-1)

This is a phase 2, 36-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the safety, tolerability, weight loss...

Active, not recruiting

Obesity or Overweight

Drug: Placebo Comparator

Drug: RGT001-075

Trial sponsors

R

C

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms